Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 4
2007 4
2008 2
2009 1
2010 3
2011 5
2012 5
2013 4
2014 2
2015 6
2016 4
2017 5
2018 8
2019 4
2020 5
2021 6
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
Dual Kinase Targeting in Leukemia.
Mologni L, Marzaro G, Redaelli S, Zambon A. Mologni L, et al. Cancers (Basel). 2021 Jan 1;13(1):119. doi: 10.3390/cancers13010119. Cancers (Basel). 2021. PMID: 33401428 Free PMC article. Review.
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini C, Brugières L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R. Karaca Atabay E, et al. Among authors: mologni l. Blood. 2022 Feb 3;139(5):717-731. doi: 10.1182/blood.2020008136. Blood. 2022. PMID: 34657149
Novel targeted therapeutics for MEN2.
Redaelli S, Plaza-Menacho I, Mologni L. Redaelli S, et al. Among authors: mologni l. Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Endocr Relat Cancer. 2018. PMID: 29348306 Review.
We shall overcome (drug resistance) some day.
Sharma GG, Mologni L. Sharma GG, et al. Among authors: mologni l. Oncotarget. 2019 Jan 4;10(2):84-85. doi: 10.18632/oncotarget.26550. eCollection 2019 Jan 4. Oncotarget. 2019. PMID: 30719203 Free PMC article. No abstract available.
Inhibitors of the anaplastic lymphoma kinase.
Mologni L. Mologni L. Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Expert Opin Investig Drugs. 2012. PMID: 22612599 Review.
RET kinase inhibitors: a review of recent patents (2012-2015).
Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L. Mologni L, et al. Expert Opin Ther Pat. 2017 Jan;27(1):91-99. doi: 10.1080/13543776.2017.1238073. Epub 2016 Sep 26. Expert Opin Ther Pat. 2017. PMID: 27646564 Review.
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.
Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L. Arosio G, et al. Among authors: mologni l. Cancers (Basel). 2021 Sep 1;13(17):4422. doi: 10.3390/cancers13174422. Cancers (Basel). 2021. PMID: 34503232 Free PMC article.
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S. Lobello C, et al. Among authors: mologni l. Leukemia. 2021 May;35(5):1500-1505. doi: 10.1038/s41375-020-01093-1. Epub 2020 Nov 27. Leukemia. 2021. PMID: 33247178 Free PMC article. No abstract available.
67 results